Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 1/2024

02-02-2024 | Antitussive | EDITORIAL

LUNG Year in Review: 2023

Author: Peter V. Dicpinigaitis

Published in: Lung | Issue 1/2024

Login to get access

Excerpt

Thanks to a dedicated editorial and production team, the year 2023 represented a period of further growth and progress at LUNG. The positive trajectory established in recent years [1] continued, as evidenced by a further significant rise in impact factor as well as strong numbers of article downloads. The acceptance rate of submitted manuscripts continued to decrease, to approximately 10%, reflecting publication of the highest quality contributions received from authors worldwide. …
Literature
1.
2.
McGarvey LP, Birring SS, Morice AH et al (2022) Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 399(10328):909–923. https://​doi.​org/​10.​1016/​S0140-6736(21)02348-5CrossRefPubMed
3.
4.
5.
6.
Kum E, Brister D, Diab N et al (2023) Canadian Health Care Professionals’ familiarity with chronic cough guidelines and experiences with diagnosis and management: a cross-sectional survey. Lung 201(1):47–55PubMedCrossRef
7.
Koskela HO, Kaulamo JT, Latti AM (2023) Cough sensitivity to several external triggers is associated with multiple non-respiratory symptoms. Lung 201(3):267–274PubMedPubMedCentralCrossRef
8.
Davila I, Puente L, Quirce S et al (2023) Characteristics and management of patients with refractory or unexplained chronic cough in outpatient hospital clinics in spain: a retrospective multicenter study. Lung 201(3):275–286PubMedPubMedCentralCrossRef
9.
Jo E-J, Lee J-H, Won H-K et al (2023) Baseline cohort profile of the korean chronic cough registry: a multicenter, prospective, observational study. Lung 201(5):477–488PubMedCrossRef
10.
Turner RD, Hirons B, Cortese A et al (2023) Chronic cough as a genetic neurological disorder? Insights from cerebellar ataxia with neuropathy and vestibular Areflexia syndrome (CANVAS). Lung 201(6):511–519PubMedPubMedCentralCrossRef
11.
Liu S, Ye X (2023) Assessment and management of cough in idiopathic pulmonary fibrosis: a narrative review. Lung 201(6):531–544PubMedCrossRef
12.
13.
Lee S-E, Rudd M, Kim T-H et al (2023) Feasibility and utility of a smartphone application-based longitudinal cough monitoring in chronic cough patients in a real-world setting. Lung 201(6):555–564PubMedCrossRef
14.
McGarvey L, Smith JA, Morice A et al (2023) A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough. Lung 201(1):25–35PubMedCrossRef
15.
McGarvey L, Sher M, Shvarts YG et al (2023) The efficacy and safety of Gefapixant in a phase 3b trial of patients with recent-onset chronic cough. Lung 201(2):111–118PubMedPubMedCentralCrossRef
16.
Dicpinigaitis PV, Morice AH, Smith JA et al (2023) Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study. Lung 201(3):255–266PubMedCrossRef
17.
18.
19.
Moller J, Hilberg O, Bendstrup E (2023) Fatigue in patients with sarcoidosis in Denmark. Lung 201(1):103–110PubMedCrossRef
20.
Shkolnik B, Sore R, Salick M et al (2023) The relationship between serum angiotensin converting enzyme level and the decision to escalate treatment of sarcoidosis. Lung 201(4):381–386PubMedCrossRef
21.
Bonas MJ, Sundaresan J, Keijsers RGM et al (2023) Methotrexate polyglutamate concentrations as a possible predictive marker for effectiveness of methotrexate therapy in patients with sarcoidosis: a pilot study. Lung 201(6):617–624CrossRef
22.
Judson MA (2023) The relationship between sarcoidosis organ involvement, environment, race, and genetics: there’s a signal. But fine tuning is needed. Lung 201(3):253–254MathSciNetPubMedCrossRef
23.
Rasmussen A, Dawkins BA, Li C et al (2023) Multiple correspondence analysis and HLA-associations of organ involvement in a large cohort of African-American and European-American patients with sarcoidosis. Lung 201(3):297–302PubMedPubMedCentralCrossRef
24.
25.
Lew D, Klang E, Soffer S et al (2023) Current applications of artificial intelligence in sarcoidosis. Lung 201(5):445–454PubMedCrossRef
26.
Judson MA, Qiu J, Dumas CL et al (2023) An artificial intelligence platform for the radiologic diagnosis of pulmonary sarcoidosis: an initial pilot study of chest computed tomography analysis to distinguish pulmonary sarcoidosis from a negative lung cancer screening scan. Lung 201(6):617–624CrossRef
27.
Martinez-Garcia MA (2023) Bronchodilators in bronchiectasis: we urgently need more trials. Lung 201(1):5–7PubMedCrossRef
28.
Shi Z-L, Zhang H-Y, Peng HB et al (2023) Tiotropium in patients with bronchiectasis: a prospective cohort study. Lung 201(1):9–15PubMedCrossRef
29.
Hill AR, Bedi P, Cartlidge MK et al (2023) Early exacerbation relapse is increased in patients with asthma and bronchiectasis (a post hoc analysis). Lung 201(1):17–23PubMedPubMedCentralCrossRef
30.
31.
Lui JK, Gillmeyer KR, Sangani RA et al (2023) A clinical decision tool for risk stratifying patients with systemic sclerosis-related pulmonary hypertension. Lung 201(6):565–569PubMedCrossRef
32.
Platenburg MGJP, van Moorsel CHM, Wiertz IA et al (2023) Improved survival of IPF patients treated with antifibrotic drugs compared with untreated patients. Lung 201(4):335–343PubMedCrossRef
33.
Huang D, Gong L, Wu Z et al (2023) Genetic association of circulating Adipokines with risk of idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study. Lung 201(4):355–362PubMedCrossRef
34.
Fan Y, Zheng C, Ma R et al (2023) MMP19 variants in familial and sporadic idiopathic pulmonary fibrosis. Lung 201(6):571–580PubMedCrossRef
35.
Khan AH, Gouia I, Kamat S et al (2023) Prevalence and severity distribution of type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis. Lung 201(1):57–63PubMedPubMedCentralCrossRef
36.
Malheiro APG, Gianfrancesco L, Nogueira RJN et al (2023) Association between serum Vitamin D levels and asthma severity and control in children and adolescents. Lung 201(2):181–187PubMedCrossRef
37.
Lin Z, Huang J, Xie S et al (2023) The association between insulin use and asthma: an epidemiological observational analysis and mendelian randomization study. Lung 201(2):189–199PubMedCrossRef
38.
Won H-K, Yoo Y, Lee J et al (2023) Clinical relevance of Staphylococcus aureus nasal colonization and staphylococcal enterotoxin-specific IgE sensitization in late-onset asthma. Lung 201(3):303–308PubMedCrossRef
39.
Kunutsor SK, Voutilainen A, Laukkanen JY (2023) Serum copper-to-zinc ratio and risk of chronic obstructive pulmonary disease: a cohort study. Lung 201(1):79–84PubMedCrossRef
40.
Li S, Huang Q, He B (2023) SIRT1 as a potential therapeutic target for chronic obstructive pulmonary disease. Lung 201(2):201–215PubMedCrossRef
41.
Garcia-Talavera I, Figueira-Goncalves JM, Golpe R et al (2023) Early desaturation during 6-minute walk test is a predictor of mortality in COPD. Lung 201(2):217–224PubMedCrossRef
42.
Garantziotis S (2023) Activated CYPD in COPD: filling in the puzzle of how perturbed epithelial respiration leads to disturbed respiratory function. Lung 201(3):251–252PubMedCrossRef
43.
Zhang R, Shan H, Li Y et al (2023) Cyclophilin D contributes to airway epithelial mitochondrial damage in chronic obstructive pulmonary disease. Lung 201(3):287–295PubMedCrossRef
44.
de la Hoz RE, Shapiro M, Nolan A et al (2023) Association of World Trade Center (WTC) occupational exposure intensity with chronic obstructive pulmonary disease (COPD) and asthma COPD overlap (ACO). Lung 201(4):325–334PubMedCrossRef
45.
Motono N, Mizoguchi T, Ishikawa M et al (2023) PD-L1 expression is not a predictive factor for recurrence in resected non-small cell lung cancer. Lung 201(1):95–101PubMedCrossRef
46.
Lee K, Haramati LB, Ye K et al (2023) Lung cancer screening penetration in an urban underserved county. Lung 201(2):243–249PubMedCrossRef
47.
Fielding D, Dalley AJ, Singh M et al (2023) Whole genome sequencing in advanced lung cancer can be performed using diff-quik cytology smears derived from endobronchial ultrasound, transbronchial needle aspiration (EBUS TBNA). Lung 201(4):407–413PubMedPubMedCentralCrossRef
48.
Cai J-S, Wang X (2023) Investigation of early-stage non-small cell lung cancer patients with different T2 descriptors: real word data from a large database. Lung 201(4):415–423PubMedCrossRef
49.
Tian W, Zhao J, Wang W (2023) Targeting CDH17 with chimeric antigen receptor-redirected T cells in small cell lung cancer. Lung 201(5):489–497PubMedCrossRef
50.
Motono N, Mizoguchi T, Ishikawa M et al (2023) Prognostic impact of cancer inflammation prognostic index for non-small cell lung cancer. Lung 201(6):603–610PubMedCrossRef
51.
Daylan AEC, Miao E, Tang K et al (2023) Lung cancer in never smokers: delving into epidemiology, genomic and immune landscape, prognosis, treatment, and screening. Lung 201(6):521–529PubMedCrossRef
52.
Ho ATN, Gorthi R, Lee R et al (2023) Solitary lung nodule: CT-guided transthoracic biopsy vs transbronchial biopsy with endobronchial ultrasound and flexible bronchoscope, a meta-analysis of randomized controlled trials. Lung 201(1):85–93PubMedCrossRef
53.
54.
Pilia E, Belletti A, Fresilli S et al (2023) The effect of heparin full-dose anticoagulation on survival of hospitalized, non-critically Ill COVID-19 patients: a meta-analysis of high quality studies. Lung 201(2):135–147PubMedPubMedCentralCrossRef
55.
Papi A, Stapleton RD, Shore PM et al (2023) Efficacy and safety of garadacimab in combination with standard of care treatment in patients with severe COVID-19. Lung 201(2):159–170PubMedPubMedCentralCrossRef
56.
Eman G, Synn S, Galen B et al (2023) Thoracic ultrasound in COVID-19: use of lung and diaphragm ultrasound in evaluating dyspnea in survivors of acute respiratory distress syndrome from COVID-19 pneumonia in a post-ICU clinic. Lung 201(2):149–157PubMedPubMedCentralCrossRef
57.
Nunez JI, Uehara M, Mohamad A et al (2023) Lactate dehydrogenase and hemorrhagic stroke during extracorporeal membrane oxygenation for COVID-19. Lung 201(4):397–406PubMedCrossRef
58.
Scialo F, Vitale M, D’Agnano V et al (2023) Lung microbiome as a treatable trait in chronic respiratory disorders. Lung 201(5):455–466PubMedCrossRef
59.
Yin L, Zhang Y, Zheng Y et al (2023) Early detection of aspergillus species in lower respiratory tract is associated with higher mortality in viral community-acquired pneumonia: a multicenter prospective cohort study in China. Lung 201(4):387–396PubMedCrossRef
60.
Roe K (2023) Increased fungal infection mortality induced by concurrent viral cellular manipulations. Lung 201(5):467–476PubMedCrossRef
61.
Friedman RS, Tarasova A, Jain VR et al (2023) Predictive value of CT biomarkers in lung transplantation survival: preliminary investigation in a diverse, underserved. Urban Popul Lung 201(6):581–590
62.
Armati M, Cattelan S, Guerrieri M et al (2023) Collagen type IV Alpha 5 chain in bronchiolitis obliterans syndrome after lung transplant: the first evidence. Lung 201(4):363–369PubMedPubMedCentralCrossRef
63.
Cui Y, Lv Z, Yang Z et al (2023) Inhibition of prostaglandin-degrading enzyme 15-PGDH mitigates acute murine lung allograft rejection. Lung 201(6):591–601PubMedCrossRef
64.
Locke BW, Sellman J, McFarland J et al (2023) Predictors of initial CPAP prescription and subsequent course with CPAP in patients with central sleep apneas at a single center. Lung 201(6):625–634PubMedCrossRef
65.
Smirnova N, Lowers J, Magee MJ et al (2023) Pulmonary function and quality of life in adults with cystic fibrosis. Lung 201(6):635–639PubMedCrossRef
66.
Bourjeily G, Sanapo L, Messerlian G et al (2023) A longitudinal study of respiratory mechanics in pregnant women with obesity and overweight. Lung 201(4):371–379PubMedCrossRef
67.
Hanon S, Verbanck S, Stylemans D et al (2023) Peak inspiratory flow for screening of inspiratory muscle weakness in neuromuscular disease. Lung 201(3):321–323PubMedCrossRef
68.
Abplanalp LA, Ionescu F, Calvo-Ayala E et al (2023) Static respiratory system compliance as a predictor of extubation failure in patients with acute respiratory failure. Lung 201(3):309–314PubMedCrossRef
69.
Saeed O, Nunez JI, Jorde UP (2023) Pulmonary protection from left ventricular distension during venoarterial extracorporeal membrane oxygenation: review and management algorithm. Lung 201(2):119–134PubMedCrossRef
70.
Akbar AF, Shou BL, Feng C-Y et al (2023) Lower oxygen tension and intracranial hemorrhage in veno-venous extracorporeal membrane oxygenation. Lung 201(3):315–320PubMedPubMedCentralCrossRef
71.
72.
73.
Zhang J, Zhou J, Yu Y et al (2023) Sesamin induces the transdifferentiation of type II alveolar epithelial cells via AnnexinA1 and TRPV1. Lung 201(1):65–77PubMedCrossRef
74.
He F, Wang Q-F, Li L et al (2023) Melatonin protects against hyperoxia-induced apoptosis in alveolar epithelial type II cells by activating the MT2/PI3K/AKT/ETS1 signaling pathway. Lung 201(2):225–234MathSciNetPubMedCrossRef
75.
Chapman R, Jones L, D’Angelo A et al (2023) Nanopore-based metagenomic sequencing in respiratory tract infection: a developing diagnostic platform. Lung 201(2):171–179PubMedPubMedCentralCrossRef
76.
Li G, Shen C, Wei D et al (2023) Deficiency of HtrA3 attenuates bleomycin-induced pulmonary fibrosis via TGF-β1/Smad signaling pathway. Lung 201(2):235–242PubMedCrossRef
77.
78.
Yang M, Chen Y, Huang X et al (2023) ETS1 ameliorates hyperoxia-induced bronchopulmonary dysplasia in mice by activating Nrf2/HO-1 mediated ferroptosis. Lung 201(4):425–441PubMedPubMedCentralCrossRef
Metadata
Title
LUNG Year in Review: 2023
Author
Peter V. Dicpinigaitis
Publication date
02-02-2024
Publisher
Springer US
Published in
Lung / Issue 1/2024
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-024-00671-9

Other articles of this Issue 1/2024

Lung 1/2024 Go to the issue

ASTHMA

Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study

DIAPHRAGM ULTRASONOGRAPHY

Diaphragm Ultrasonography: Reference Values and Influencing Factors for Thickness, Thickening Fraction, and Excursion in the Seated Position

BRONCHIECTASIS

Elevated Eosinophil Counts in Acute Exacerbations of Bronchiectasis: Unveiling a Distinct Clinical Phenotype

STATE OF THE ART REVIEW: THE THERAPEUTIC LANDSCAPE IN CHRONIC COUGH

The Therapeutic Landscape in Chronic Cough

INTERVENTIONAL PULMONOLOGY

Transbronchial Lung Cryobiopsy Performed with Cone Beam Computed Tomography Guidance Versus Fluoroscopy: A Retrospective Cohort Review

INTERSTITIAL LUNG DISEASE

Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits